Treating multiple sclerosis with monoclonal antibodies: a 2010 update
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treating multiple sclerosis with monoclonal antibodies: a 2010 update
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 10, Issue 5, Pages 791-809
Publisher
Informa UK Limited
Online
2010-04-26
DOI
10.1586/ern.10.38
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
- (2010) Daniel Wynn et al. LANCET NEUROLOGY
- Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study
- (2010) Samantha Jilek et al. LANCET NEUROLOGY
- SEVERE CUTANEOUS CANDIDA INFECTION DURING NATALIZUMAB THERAPY IN MULTIPLE SCLEROSIS
- (2010) S. Gutwinski et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapie der Multiplen Sklerose mit monoklonalen Antikörpern
- (2009) R. Gold et al. AKTUELLE NEUROLOGIE
- Primary central nervous system lymphoma in a patient treated with natalizumab
- (2009) Andreas Schweikert et al. ANNALS OF NEUROLOGY
- Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo
- (2009) Monika Bradl et al. ANNALS OF NEUROLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Effector Functions of Antiaquaporin-4 Autoantibodies in Neuromyelitis Optica
- (2009) Romain Cayrol et al. Annals of the New York Academy of Sciences
- Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
- (2009) Eugene O. Major Annual Review of Medicine
- Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro
- (2009) M. Brickelmaier et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Regulatory T Cells Are Reduced During Anti-CD25 Antibody Treatment of Multiple Sclerosis
- (2009) Unsong Oh et al. ARCHIVES OF NEUROLOGY
- Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis
- (2009) Bibiana Bielekova et al. ARCHIVES OF NEUROLOGY
- Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases
- (2009) Eamonn S. Molloy et al. ARTHRITIS AND RHEUMATISM
- Immune reconstitution syndrome and the thyroid
- (2009) Anthony Weetman BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Neuromyelitis optica: Passive transfer to rats by human immunoglobulin
- (2009) Makoto Kinoshita et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Ustekinumab
- (2009) Juliane Weber et al. BIODRUGS
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
- (2009) K. R. Carson et al. BLOOD
- Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope
- (2009) Susumu Uchiyama et al. CANCER SCIENCE
- Ustekinumab
- (2009) Anna L. Chien et al. DRUGS
- Melanoma following treatment with alemtuzumab for multiple sclerosis
- (2009) A. A. Pace et al. EUROPEAN JOURNAL OF NEUROLOGY
- Ocrelizumab: a step forward in the evolution of B-cell therapy
- (2009) Fariha Kausar et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders
- (2009) Jorge Castillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
- (2009) Erin E Longbrake et al. Expert Review of Neurotherapeutics
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
- (2009) Sara A. J. Thompson et al. JOURNAL OF CLINICAL IMMUNOLOGY
- B Cell Receptor and BAFF Receptor Signaling Regulation of B Cell Homeostasis
- (2009) W. N. Khan JOURNAL OF IMMUNOLOGY
- Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
- (2009) A. W. Pawluczkowycz et al. JOURNAL OF IMMUNOLOGY
- Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
- (2009) Adrian Egli et al. JOURNAL OF INFECTIOUS DISEASES
- Unmasking of PML by HAART: Unusual clinical features and the role of IRIS
- (2009) Navdeesh Sidhu et al. JOURNAL OF NEUROIMMUNOLOGY
- Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis
- (2009) Azza Ismail et al. JOURNAL OF NEUROLOGY
- Glatiramer acetate treatment in PPMS: Why males appear to respond favorably
- (2009) Jerry S. Wolinsky et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
- (2009) Kenneth R Carson et al. LANCET ONCOLOGY
- Daclizumab in treatment of multiple sclerosis patients
- (2009) EN Ali et al. Multiple Sclerosis Journal
- Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?
- (2009) Roberto Bergamaschi et al. Multiple Sclerosis Journal
- Mitoxantrone: benefits and risks in multiple sclerosis patients
- (2009) V. Martinelli et al. NEUROLOGICAL SCIENCES
- Iatrogenic immunosuppression with biologics in MS: Expecting the unexpected?
- (2009) O. Stuve et al. NEUROLOGY
- Natalizumab: Bound to rebound?
- (2009) N. Schiess et al. NEUROLOGY
- The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
- (2009) E. C. Klawiter et al. NEUROLOGY
- GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study
- (2009) A. D. Goodman et al. NEUROLOGY
- OCULAR TOXOPLASMOSIS DURING NATALIZUMAB TREATMENT
- (2009) C. Zecca et al. NEUROLOGY
- Determinants of survival in progressive multifocal leukoencephalopathy
- (2009) A. Marzocchetti et al. NEUROLOGY
- Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: Outcome and epidemiology
- (2009) J. A. McCombe et al. NEUROLOGY
- Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
- (2009) Yiping Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
- (2009) Werner Wenning et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
- (2009) Hans Lindå et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis
- (2008) Andrea De Luca et al. AIDS
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- Interleukin 21 as a target of intervention in autoimmune disease
- (2008) R Ettinger et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment of Neuromyelitis Optica With Rituximab
- (2008) ARCHIVES OF NEUROLOGY
- Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk?
- (2008) Eamonn S. Molloy et al. AUTOIMMUNITY REVIEWS
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
- (2008) A. Hagenbeek et al. BLOOD
- Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity
- (2008) M. Krumbholz et al. BRAIN
- Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody
- (2008) Wim K. Bleeker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treating multiple sclerosis with monoclonal antibodies
- (2008) Mathias Buttmann et al. Expert Review of Neurotherapeutics
- Advances in the pathogenesis of Goodpasture's disease: From epitopes to autoantibodies to effector T cells
- (2008) Joshua D. Ooi et al. JOURNAL OF AUTOIMMUNITY
- Incidence, Clinical Presentation, and Outcome of Progressive Multifocal Leukoencephalopathy in HIV-Infected Patients during the Highly Active Antiretroviral Therapy Era: A Nationwide Cohort Study
- (2008) Frederik Neess Engsig et al. JOURNAL OF INFECTIOUS DISEASES
- Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis
- (2008) C. L. Hirst et al. JOURNAL OF NEUROLOGY
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) G Comi et al. LANCET
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) Ludwig Kappos et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
- (2008) Benjamin M Segal et al. LANCET NEUROLOGY
- Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
- (2008) Clive S. Zent et al. LEUKEMIA RESEARCH
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
- (2008) O. Stuve et al. NEUROLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
- (2008) John T. Mullen et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interferon β1-a and selective anti-5HT2a receptor antagonists inhibit infection of human glial cells by JC virus
- (2008) B.A. O’Hara et al. VIRUS RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started